ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access

Kancharla Suresh1, Yapadinna Vimala1, Nitin Mohan2 and Indugula Jyothi Padmaja2

1Department of Microbiology, GITAM institute of Science, GITAM (Deemed to be University), Gandhinagar campus, Rushikonda, Visakhapatnam – 530 045, Andhra Pradesh, India.
2Department of Microbiology, GITAM Institute of Medical Sciences & Research, GITAM (Deemed to be University), Gandhinagar campus, Rushikonda, Visakhapatnam – 530 045, Andhra Pradesh, India.
J Pure Appl Microbiol. 2021;15(1):68-74 | Article Number: 6500
https://doi.org/10.22207/JPAM.15.1.01 | © The Author(s). 2021
Received: 25/06/2020 | Accepted: 10/11/2020 | Published: 25/01/2021
Abstract

Fluoroquinolones (FQ) are integral part of multidrug resistant/rifampicin resistant tuberculosis (MDR-TB/RR TB) treatment regimens. FQ resistance in MDR-TB lead to narrower treatment options and poor treatment outcomes. Hence proportion of FQ resistance among MDR-TB and cross-resistance among FQ in MDR-TB isolates was studied. This is the first study from North Coastal Andhra Pradesh, India. A cross-sectional study was conducted on 21,474 sputum samples from January-December 2018 & 833 culture isolates (rifampicin resistant detected by GeneXpert MTB / RIF assay & MDR-TB detected by direct and indirect GenoType MTBDRplus Assay) were analysed for FQ resistance by Mycobacterium Growth Indicator Tube (MGIT) for ofloxacin (Ofx) 2.0 µg/mL, levofloxacin (Lfx) 1.5 µg/mL & moxifloxacin (Mfx) 2.0 μg/mL. Among 833 culture isolates, 119 (14.2%) showed resistance to FQ which included 90 (10.8%) Ofx and Lfx resistance isolates but still sensitive to Mfx, 16 (1.92%) with resistance to all FQ tested, 12 Ofx monoresistance & 1 Lfx monoresistance. Mfx monoresistance was absent. Mfx sensitive isolates are 714 (85.7%) and were always sensitive to Ofx and Lfx. Cross-resistance was not complete. MDR-TB/RR TB is 4.1% among all TB patients. Additional resistance to FQ, among MDR-TB patients was seen in 14.2% patients.

Keywords

Multidrug-resistant tuberculosis, fluoroquinolones, MGIT 960, cross-resistance

Article Metrics

Article View: 49

Share This Article

© The Author(s) 2021. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.